

**From:** Amgen Inc.  
**To:** <Professional Society email>  
**Subject:** WARNING: Serious Risks Associated with BLINCYTO®



## BLINCYTO® (blinatumomab) REMS

### FDA-REQUIRED REMS SAFETY INFORMATION

**Risk of:**

- **Cytokine Release Syndrome (CRS), which may be life-threatening or fatal**
- **Neurological Toxicities, which may be severe, life-threatening or fatal**
- **Preparation and Administration Errors**

August 2016

### IMPORTANT SAFETY NOTICE

Dear [name]:

The FDA has required this safety notice as part of the **BLINCYTO® REMS** (**R**isk **E**valuation and **M**itigation **S**trategy) to be distributed to the [insert Professional Society Name]. Amgen requests that you distribute the information to your members, informing them about the serious risks of BLINCYTO.

### BOXED WARNING: Cytokine Release Syndrome

- Serious adverse events that may be associated with CRS included **pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin.**
- The highest elevation of cytokines was observed in the first 2 days following start of BLINCYTO infusion.

- Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle.

### **BOXED WARNING: Neurological Toxicities**

- In patients receiving BLINCYTO in clinical trials, neurological toxicities have occurred in approximately 64% of patients.
- The median time to onset of any neurological toxicity was 4 days.
- Grade 3 or higher (severe, life-threatening or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 17% of patients and included **encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders**. The majority of events resolved following interruption of BLINCYTO, but some resulted in treatment discontinuation.

**Monitor patients closely for signs and symptoms of these events and interrupt or discontinue dosing of BLINCYTO.**

### **OTHER SERIOUS RISKS: Preparation and Administration Errors**

- **It is very important that the instruction for preparation (including admixing) and administration are strictly followed to minimize medication errors (including underdose and overdose).**
- Please note that the recommended dose for BLINCYTO is by patient weight. Patients greater than or equal to 45 kg receive a fixed-dose and for patients less than 45 kg, the dose is calculated using the patient's body surface area (BSA).

Please see the non-promotional REMS Fact Sheet, reviewed by the FDA available at [www.blincytoREMS.com](http://www.blincytoREMS.com) and the full Prescribing Information for more detailed safety information. Additional copies of the Fact Sheet and other important information are available at: [www.blincytoREMS.com](http://www.blincytoREMS.com).

BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Sincerely,

Isma Benattia, MD, MBE  
Vice President, Global Patient Safety

BLINCYTO® is a trademark of Amgen Inc.  
©2016 Amgen Inc. All rights reserved.



## BLINCYTO<sup>®</sup> (blinatumomab) REMS

### FDA-REQUIRED REMS SAFETY INFORMATION

**Risk of:**

- Cytokine Release Syndrome (CRS), which may be life-threatening or fatal
- Neurological Toxicities, which may be severe, life-threatening or fatal
- Preparation and Administration Errors

August 2016

#### IMPORTANT SAFETY NOTICE

Dear <name>

The FDA has required this safety notice as part of the BLINCYTO<sup>®</sup> REMS (Risk Evaluation and Mitigation Strategy) to be distributed to the <insert Professional Society Name>. Amgen requests that you distribute the information to your members, informing them about the serious risks of BLINCYTO.

#### BOXED WARNING: Cytokine Release Syndrome

- Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin.
- The highest elevation of cytokines was observed in the first 2 days following start of BLINCYTO infusion.
- Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle.

#### BOXED WARNING: Neurological Toxicities

- In patients receiving BLINCYTO in clinical trials, neurological toxicities have occurred in approximately 64% of patients.
- The median time to onset of any neurological toxicity was 4 days.
- Grade 3 or higher (severe, life-threatening or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 17% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. The majority of events resolved following interruption of BLINCYTO, but some resulted in treatment discontinuation.

Monitor patients closely for signs and symptoms of these events and interrupt or discontinue dosing of BLINCYTO.

#### **OTHER SERIOUS RISKS: Preparation and Administration Errors**

- It is very important that the instruction for preparation (including admixing) and administration are strictly followed to minimize medication errors (including underdose and overdose).
- Please note that the recommended dose for BLINCYTO is by patient weight. Patients greater than or equal to 45 kg receive a fixed-dose and for patients less than 45 kg, the dose is calculated using the patient's body surface area (BSA).

Please see the enclosed non-promotional REMS Fact Sheet, reviewed by the FDA and the full Prescribing Information for more detailed safety information. Additional copies of the Fact Sheet and other important information are available at: [www.blincyto.rems.com](http://www.blincyto.rems.com).

BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Sincerely,

Isma Benattia, MD, MBE  
Vice President, Global Patient Safety